Twenty-four patients with pleural mesothelioma received 50 mg/m2 of Doxil® every four weeks. At follow-up, the disease had stabilized in 43% percent of patients and had progressed in 57%. No objective responses were observed. Estimated median survival of all patients was 37 weeks. Major toxicities were erythrodysesthesia of hands and feet and myelosuppression. No cardiac toxicity was observed. We concluded that Doxil® at this dosage and schedule is inactive against pleural mesothelioma.
ASJC Scopus subject areas
- Pharmacology (medical)